Search

Your search keyword '"Newitt, John A."' showing total 39 results

Search Constraints

Start Over You searched for: Author "Newitt, John A." Remove constraint Author: "Newitt, John A." Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
39 results on '"Newitt, John A."'

Search Results

3. Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1

4. The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer

6. Assessing compound binding to the Eg5 motor domain using a thermal shift assay

8. Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1)

9. Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis

10. The structure and multiple polypeptide domains determines the signal recognition particle targeting requirement of Escherichia coli inner membrane proteins

11. The E. coli signal recognition particle is required for the insertion of a subset of inner membrane proteins

12. Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1).

13. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core

14. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode

17. Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer

18. Development of a Model Protein Interaction Pair as a Benchmarking Tool for the Quantitative Analysis of 2-Site Protein-Protein Interactions

19. Discovery of Novel P1 Groups for Coagulation Factor VIIa Inhibition Using Fragment-Based Screening

20. Discovery of pyrrolo[2,1- f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors

21. 5-Amino-pyrazoles as potent and selective p38α inhibitors

22. Utilization of a nitrogen–sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors

23. The discovery of ( R)-2-( sec-butylamino)- N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)—A potent and efficacious p38α MAP kinase inhibitor

24. Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases

25. Multiple and Single Binding Modes of Fragment-Like Kinase Inhibitors Revealed by Molecular Modeling, Residue Type-Selective Protonation, and Nuclear Overhauser Effects

27. Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors

29. Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors

30. The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants

31. Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series

36. The E. coli signal recognition particle is required for the insertion of the subset of inner...

38. A Mutation in the Escherichia coli secYGene That Produces Distinct Effects on Inner Membrane Protein Insertion and Protein Export*

39. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.

Catalog

Books, media, physical & digital resources